Laparoscopic gastric bypass results in decreased prescription medication costs within 6 months
Department of Surgery, University of Wisconsin–Madison, Madison, Wisconsin, United States Journal of Gastrointestinal Surgery
(Impact Factor: 2.8).
01/2005; 8(8):983-7. DOI: 10.1016/j.gassur.2004.09.042
The prevalence of obesity has reached epidemic proportions. The treatment of obesity-related health conditions is costly. Although laparoscopic gastric bypass is expensive, health care costs in obese patients should decrease with subsequent weight loss and overall improved health. Specifically, monthly prescription medication costs should decrease quickly after surgery. Fifty consecutive laparoscopic gastric bypass patients at a university-based bariatric surgery program were enrolled in the study. Medication consumption was prospectively recorded in a database. Patients' monthly prescription (not over-the-counter) medication costs before surgery and 6 months postoperatively were calculated. Retail costs were determined by a query to drugstore.com, an online pharmacy. Generic drugs were selected when appropriate. Costs for diabetic supplies and monitoring were not included in this analysis. Patients were mostly female (86%). Mean body mass index preoperatively was 51 kg/m2. Mean excess weight loss at 6 months was 52%. Patients took an average of 3.7 prescription medications before surgery compared with 1.7 after surgery (P < 0.05). All patients took nonprescription nutritional supplements, including multivitamins, oral vitamin B12, and calcium postoperatively. Laparoscopic gastric bypass resulted in a significant improvement in comorbid health conditions as early as 6 months after surgery. In an unselected group of patients, this led to a substantial overall mean monthly prescription medication cost savings, especially in those with gastroesophageal reflux disease, hypertension, diabetes, and hypercholesterolemia.
Available from: Airton T Stein
- "In a study of 50 patients, Gould et al. (2004) found that among 16 patients using a proton-pump inhibitor preoperatively, only two (because of the development of a marginal ulcer) continued the treatment postoperatively . According to Nguyen et al., 93 % of the 43 individuals with GERD were able to discontinue drug use 1 year after surgery . "
[Show abstract] [Hide abstract]
ABSTRACT: The aim of this study was to assess drug use and costs before and after bariatric surgery (BS). A systematic review of the literature was carried out using the MeSH terms obesity, bariatric surgery, and drug costs for searches of 10 electronic databases up to July 2014. Data were extracted from the 11 studies (37,720 patients) that fulfilled the inclusion criteria. Where applicable, data were pooled by meta-analysis. The average number of drugs per patient decreased from 3.9 ± 1.86 before surgery to 1.75 ± 1.85 after surgery. Mean reduction in total cost of drugs was 49.8 % over a follow-up duration of 6-72 months. BS is effective for the improvement or resolution of comorbidities and significantly reduces drug use and costs.
Obesity Surgery 06/2015; 25(9). DOI:10.1007/s11695-015-1777-5 · 3.75 Impact Factor
Available from: Michael M Meguid
- "Alterations in gut peptide concentrations and reversal of glucose intolerance occur before significant weight loss  . Monthly prescription medication costs are decreased significantly by 6 months after RYGB, supporting this procedure's cost-effectiveness ; however, persistent failure rates (complications or weight gain) vary with the type of bariatric procedure performed . Research on the neurohormonal mechanisms regulating food intake is critical to sharpen our putative understanding of which operative procedure is optimal and whether these procedures need to be modified to improve long-term weight maintenance and overall operative outcomes. "
Surgery for Obesity and Related Diseases 09/2005; 1(5):486-95. DOI:10.1016/j.soard.2005.05.009 · 4.07 Impact Factor
Surgery for Obesity and Related Diseases 09/2005; 1(5):453-7. DOI:10.1016/j.soard.2005.07.005 · 4.07 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.